Education
About Us
Working with TipRanks
Follow Us
Nuvalent, Inc. Class A (NUVL)
NASDAQ:NUVL
NUVL Stock Chart & Stats
$102.26
-$0.36(-0.45%)
At close: 4:00 PM EST
$102.26
-$0.36(-0.45%)
Day’s Range― - ―
52-Week Range$55.54 - $113.02
Previous CloseN/A
Volume65.93K
Average Volume (3M)485.30K
Market Cap
$8.04B
Enterprise Value$7.22B
Total Cash (Recent Filing)$1.37B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.99
Next Earnings
May 07, 2026EPS Estimate
-1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.58
Shares Outstanding73,181,750
10 Day Avg. Volume509,688
30 Day Avg. Volume485,300
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)5.86
Price to Sales (P/S)0.00
P/FCF Ratio-26.57
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-21.37
Forecast
1Y Price Target
$142.31Price Target Upside39.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-5.55
Revenue Forecast (FY)$13.91M
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationAnalyst highlights that zidesamtinib offers superior brain penetration and higher, more durable response rates in patients with brain metastases and those resistant to prior targeted therapies, suggesting a clear clinical advantage over existing options.
Commercial Readiness And FundingCompany's strong cash position, active scaling of commercial operations including a growing sales team, and an extensive expanded access program that may convert patients to commercial users support a well-resourced potential product launch.
Regulatory And Label ExpansionAnalyst expects regulatory approval for zidesamtinib in pretreated ROS1-positive lung cancer and cites a planned supplemental filing to expand use into patients without prior targeted therapy, potentially broadening the label and patient pool.
Bears Say
Management Transparency On Regulatory MattersManagement has not asked the FDA why zidesamtinib received a standard review, creating ambiguity around the regulatory pathway and elevating execution risk.
Pipeline Development RiskForthcoming development candidate targets a higher-risk oncology target than ALK and ROS, increasing the probability of clinical setbacks and adding uncertainty to pipeline progress.
Regulatory Timing RiskApprovals and launches hinge on regulatory review timelines, so extended reviews or unfavorable designations could delay market entry and revenue realization.
Nuvalent News
NUVL FAQ
What was Nuvalent, Inc. Class A’s price range in the past 12 months?
Nuvalent, Inc. Class A lowest stock price was $55.53 and its highest was $113.02 in the past 12 months.
What is Nuvalent, Inc. Class A’s market cap?
Nuvalent, Inc. Class A’s market cap is $8.04B.
When is Nuvalent, Inc. Class A’s upcoming earnings report date?
Nuvalent, Inc. Class A’s upcoming earnings report date is May 07, 2026 which is in 56 days.
How were Nuvalent, Inc. Class A’s earnings last quarter?
Nuvalent, Inc. Class A released its earnings results on Feb 26, 2026. The company reported -$1.58 earnings per share for the quarter, missing the consensus estimate of -$1.476 by -$0.104.
Is Nuvalent, Inc. Class A overvalued?
According to Wall Street analysts Nuvalent, Inc. Class A’s price is currently Undervalued.
Does Nuvalent, Inc. Class A pay dividends?
Nuvalent, Inc. Class A does not currently pay dividends.
What is Nuvalent, Inc. Class A’s EPS estimate?
Nuvalent, Inc. Class A’s EPS estimate is -1.35.
How many shares outstanding does Nuvalent, Inc. Class A have?
Nuvalent, Inc. Class A has 73,181,750 shares outstanding.
What happened to Nuvalent, Inc. Class A’s price movement after its last earnings report?
Nuvalent, Inc. Class A reported an EPS of -$1.58 in its last earnings report, missing expectations of -$1.476. Following the earnings report the stock price went down -0.574%.
Which hedge fund is a major shareholder of Nuvalent, Inc. Class A?
Currently, no hedge funds are holding shares in NUVL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvalent Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$142.31 (39.16% Upside)
$142.31 (39.16% Upside)
Blogger Sentiment
Bullish
NUVL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 205.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.76%
12-Months-Change
Fundamentals
Return on Equity
-42.07%
Trailing 12-Months
Asset Growth
23.73%
Trailing 12-Months
Company Description
Nuvalent, Inc. Class A
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
NUVL Stock 12 Month Forecast
Average Price Target
$142.31
▲(39.16% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---